Researchers at the University of Minnesota’s Center for Drug Design have developed a new method to combat HIV/AIDS, potentially replacing the traditional cocktail drug approach.
The new approach – proven accurate in lab tests – merges the features of two antiviral agents into one drug, achieving the same effect as when two or more drugs are taken separately. The cocktail approach most commonly prescribed to HIV-infected patients is expensive and high in toxicity because many drugs are taken at one time.
The researchers named the new concept Portmanteau Inhibitors, and the results were published in a July 4 issue of the Journal of Medicinal Chemistry. The principal researcher is Robert Vince, Ph.D., director of the center and a professor of medicinal chemistry in the College of Pharmacy.
“It’s one drug that does the same thing as two independent drugs would do,” Vince said. “It’s a new approach in HIV/AIDS treatment.”
Besides remedying cost and toxicity problems, a Portmanteau Inhibitor is less likely to develop resistance from the virus because of its multifaceted approach. Most importantly, research found that the separate components of the drug did not interfere with each other while attacking HIV.
“One drug is not durable. It develops resistance very quickly,” said Zhenqiang Wang, Ph.D., a researcher in the Center for Drug Design, and co-investigator of the research. “This makes it much more difficult for resistance to develop.”
The next step will be more research and testing to see how the drug reacts once distributed in the body. But, preliminary research and confirmation of the new concept shows promise because the quality of life for AIDS patients hinges on low costing medication and minimal side effects, Wang said.
“It’s huge,” he said. “This concept could lead to a replacement for the cocktail treatment.”
Source: University of Minnesota
Related stories:
A breakthrough, then a surge, in stem cell research
Less than a year after a Wisconsin team helped discover a major alternative to human embryonic stem cells, the Madison scientists say more than 800 labs have begun using the approach, suggesting that many stem-cell researchers are starting to move beyond controversial embryonic sources for their work.
Nanotechnology boosts war on superbugs
This week
Nature Nanotechnology journal (October 12th) reveals how scientists from the London Centre for Nanotechnology (LCN) at UCL are using a novel nanomechanical approach to investigate the workings of vancomycin, one of the few antibiotics that can be used to combat increasingly resistant infections such as MRSA. The researchers, led by Dr Rachel McKendry and Professor Gabriel Aeppli, developed ultra-sensitive probes capable of providing new insight into how antibiotics work, paving the way for the development of more effective new drugs.
Limit on cold remedies for kids was FDA's idea
(AP) -- When drug makers made a surprise announcement this week that they no longer recommend cough and cold remedies for youngsters under 4, they didn't let on that it was the government's idea.
Anti-cancer drug prevents, reverses cardiovascular damage in mouse model of premature aging disorder
An experimental anti-cancer drug can prevent -- and even reverse -- potentially fatal cardiovascular damage in a mouse model of progeria, a rare genetic disorder that causes the most dramatic form of human premature aging, National Institutes of Health (NIH) researchers reported today.
Nanodiamond drug device could transform cancer treatment
A Northwestern University research team has developed a promising nanomaterial-based biomedical device that could be used to deliver chemotherapy drugs locally to sites where cancerous tumors have been surgically removed.
Groundbreaking discovery may lead to stronger antibiotics
The last decade has seen a dramatic decline in the effectiveness of antibiotics, resulting in a mounting public health crisis across the world. A new breakthrough by University of Virginia researchers provides physicians and patients a potential new approach toward the creation of less resistant and more effective antibiotics.
'Hub' of fear memory formation identified in brain cells
A protein required for the earliest steps in embryonic development also plays a key role in solidifying fear memories in the brains of adult animals, scientists have revealed. An apparent "hub" for changes in the connections between brain cells, beta-catenin could be a potential target for drugs to enhance or interfere with memory formation.
Existing anti-obesity drugs may be effective against flu, hepatitis and HIV
Viruses dramatically increase cellular metabolism, and existing anti-obesity drugs may represent a new way to block these metabolic changes and inhibit viral infection, according to a study published today in the journal
Nature Biotechnology.